Key facts
- This page summarizes Alexander J. Denner's Form 4 filing for BIOGEN INC. (BIIB).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 Jun 2022, 16:29.
Alexander J. Denner - 15 Jun 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)
- Reporting relationship
- Director
- Issuer ticker
- BIIB
- Reported as of
- 15 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2022, 16:29:01 UTC
- Prior SEC filing
- 03 Jun 2022
- Next SEC filing
- 19 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Wendell Taylor, Attorney in Fact for Alexander J. Denner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alexander J. Denner filed Form 4 for BIOGEN INC. (BIIB) on 17 Jun 2022.
Change
- Previous filing in this sequence was filed on 03 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIIB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,370
- Change %
- +10%
- Price
- $0.000000
- Shares after
- 15,099
- Date
- 15 Jun 2022
- Ownership
- Direct
BIIB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 643,000
- Date
- 15 Jun 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein.
Footnote F2
Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the "Sarissa Funds"). Alexander Denner is the Chief Investment Officer of Sarissa Capital and controls the ultimate general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own.